[HLFG] YoY Annualized Quarter Result on 31-Dec-2017 [#2]

Announcement Date
26-Feb-2018
Admission Sponsor
-
Sponsor
-
Financial Year
30-Jun-2018
Quarter
31-Dec-2017 [#2]
Profit Trend
QoQ- 4.4%
YoY- 14.64%
View:
Show?
Annualized Quarter Result
31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 31/12/15 31/12/14 CAGR
Revenue 6,236,354 5,372,334 5,256,914 5,289,534 5,071,830 4,623,304 4,452,120 5.77%
PBT 3,909,960 3,675,762 3,613,260 3,530,378 3,116,016 2,368,670 3,086,230 4.01%
Tax -609,938 -674,436 -610,160 -650,630 -621,810 -412,502 -643,102 -0.87%
NP 3,300,022 3,001,326 3,003,100 2,879,748 2,494,206 1,956,168 2,443,128 5.13%
-
NP to SH 2,229,230 1,986,322 1,974,484 1,901,190 1,658,450 1,300,662 1,631,988 5.33%
-
Tax Rate 15.60% 18.35% 16.89% 18.43% 19.96% 17.41% 20.84% -
Total Cost 2,936,332 2,371,008 2,253,814 2,409,786 2,577,624 2,667,136 2,008,992 6.52%
-
Net Worth 21,780,085 19,799,451 18,595,430 17,327,505 16,179,988 14,074,607 12,098,498 10.28%
Dividend
31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 31/12/15 31/12/14 CAGR
Div 244,898 295,344 298,261 298,354 298,354 280,413 272,347 -1.75%
Div Payout % 10.99% 14.87% 15.11% 15.69% 17.99% 21.56% 16.69% -
Equity
31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 31/12/15 31/12/14 CAGR
Net Worth 21,780,085 19,799,451 18,595,430 17,327,505 16,179,988 14,074,607 12,098,498 10.28%
NOSH 1,147,516 1,147,516 1,147,516 1,147,516 1,147,516 1,147,516 1,047,489 1.53%
Ratio Analysis
31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 31/12/15 31/12/14 CAGR
NP Margin 52.92% 55.87% 57.13% 54.44% 49.18% 42.31% 54.88% -
ROE 10.24% 10.03% 10.62% 10.97% 10.25% 9.24% 13.49% -
Per Share
31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 31/12/15 31/12/14 CAGR
RPS 550.05 472.94 458.26 460.95 441.98 428.67 425.03 4.38%
EPS 196.60 174.80 172.40 166.20 145.00 122.40 155.80 3.94%
DPS 21.60 26.00 26.00 26.00 26.00 26.00 26.00 -3.04%
NAPS 19.21 17.43 16.21 15.10 14.10 13.05 11.55 8.84%
Adjusted Per Share Value based on latest NOSH - 1,147,516
31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 31/12/15 31/12/14 CAGR
RPS 543.47 468.17 458.11 460.95 441.98 402.90 387.98 5.77%
EPS 194.27 173.10 172.07 166.20 145.00 113.35 142.22 5.33%
DPS 21.34 25.74 25.99 26.00 26.00 24.44 23.73 -1.75%
NAPS 18.9802 17.2542 16.2049 15.10 14.10 12.2653 10.5432 10.28%
Price Multiplier on Financial Quarter End Date
31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 31/12/15 31/12/14 CAGR
Date 31/12/20 31/12/19 31/12/18 29/12/17 30/12/16 31/12/15 31/12/14 -
Price 18.06 16.90 18.56 17.88 14.22 13.96 16.52 -
P/RPS 3.28 3.57 4.05 3.88 3.22 3.26 3.89 -2.80%
P/EPS 9.19 9.66 10.78 10.79 9.84 11.58 10.60 -2.34%
EY 10.89 10.35 9.27 9.27 10.16 8.64 9.43 2.42%
DY 1.20 1.54 1.40 1.45 1.83 1.86 1.57 -4.37%
P/NAPS 0.94 0.97 1.14 1.18 1.01 1.07 1.43 -6.74%
Price Multiplier on Announcement Date
31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 31/12/15 31/12/14 CAGR
Date 26/02/21 26/02/20 26/02/19 26/02/18 21/02/17 23/02/16 25/02/15 -
Price 16.96 15.70 20.10 18.46 15.20 14.14 16.76 -
P/RPS 3.08 3.32 4.39 4.00 3.44 3.30 3.94 -4.01%
P/EPS 8.63 8.98 11.68 11.14 10.52 11.72 10.76 -3.60%
EY 11.59 11.14 8.56 8.98 9.51 8.53 9.30 3.73%
DY 1.27 1.66 1.29 1.41 1.71 1.84 1.55 -3.26%
P/NAPS 0.88 0.90 1.24 1.22 1.08 1.08 1.45 -7.97%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ & YoY figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment